ANA AMELIA FIALHO DE OLIVEIRA HOFF

(Fonte: Lattes)
Índice h a partir de 2011
20
Projetos de Pesquisa
Unidades Organizacionais
Instituto do Câncer do Estado de São Paulo, Hospital das Clínicas, Faculdade de Medicina - Médico

Resultados de Busca

Agora exibindo 1 - 1 de 1
  • article 83 Citação(ões) na Scopus
    Epidemiology and risk factors for osteonecrosis of the jaw in cancer patients
    (2011) HOFF, Ana O.; TOTH, Bela; HU, Mimi; HORTOBAGYI, Gabriel N.; GAGEL, Robert F.
    Osteonecrosis of the jaw (ONJ), previously an entity associated with radiation therapy to the head and neck, has been observed in patients treated with bisphosphonates. Patients with metastatic breast cancer and myelomatous bone disease, commonly treated with high-potency nitrogen-containing bisphosphonates for a prolonged period of time, have the greatest risk of ONJ development. The reported frequency of ONJ ranges from 0.6% to 6.2% in breast cancer and from 1.7% to 15% in patients with multiple myeloma. Osteonecrosis of the jaw has also been observed in patients with other cancers such as prostate cancer and in benign bone disorders such as osteoporosis and Paget's disease in which the incidence is low. Risk factors associated with the development of ONJ include dental extractions, length of bisphosphonate treatment, and the type of bisphosphonate used. In this review, we summarize the reported incidence and risk factors associated with ONJ.